Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication July 23, 2015
- Accepted for publication August 26, 2015
- Published online February 1, 2016.
Copyright & Usage
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Author Information
- Gary A. Ulaner1,2,
- Chris C. Riedl1,
- Maura N. Dickler3,
- Komal Jhaveri3,
- Neeta Pandit-Taskar1,2 and
- Wolfgang Weber1,2
- 1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
- 2Department of Radiology, Weill Cornell Medical College, New York, New York; and
- 3Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
- For correspondence or reprints contact: Gary Ulaner, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10065. E-mail: ulanerg{at}mskcc.org
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
- Article
- Abstract
- WHAT ARE BIOMARKERS?
- TISSUE- AND BLOOD-BASED PROGNOSTIC AND PREDICTIVE BIOMARKERS IN BREAST CANCER
- POTENTIAL OF PROGNOSTIC AND PREDICTIVE MOLECULAR IMAGING BIOMARKERS
- ASSESSMENT OF DISEASE RESPONSE TO NEOADJUVANT THERAPY
- BIOMARKERS FOR MONITORING DISEASE RESPONSE IN METASTATIC BREAST CANCER
- POTENTIAL OF MOLECULAR IMAGING FOR MONITORING DISEASE RESPONSE IN METASTATIC BREAST CANCER
- ROLE OF MOLECULAR IMAGING BIOMARKERS IN CLINICAL TRIALS OF NOVEL THERAPEUTICS
- LIMITATIONS AND CHALLENGES
- CONCLUSION
- DISCLOSURE
- REFERENCES
- Figures & Data
- Info & Metrics
Related Articles
Cited By...
- Head-to-Head Evaluation of 18F-FES and 18F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer
- Elevated soluble Galectin-3 as a marker of chemotherapy efficacy in Breast cancer patients; a prospective study
- First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer
- Molecular Imaging of GLUT1 and GLUT5 in Breast Cancer: A Multitracer Positron Emission Tomography Imaging Study in Mice
- Prospective Clinical Trial of 18F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers
- 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials
- Introduction and Overview